An observational study in Osteoarthritis, sponsored by Boehringer Ingelheim. Completed. Per ClinicalTrials.gov, last updated 2014-07-21.
Sponsored by Boehringer Ingelheim · Observational
The USAGE study aims at assessing on a long-term period (two years in average) the outcome in clinical or economical term of patients with knee osteoarthritis (OA) treated or not with Synvisc®, in the 1139.4 clinical trial.
4,398 studies on the registry are indexed under Osteoarthritis; 583 are open to participants now.
This study's enrollment of 374 is above the median of 100 across 792 observational studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
rheumatological practice
Exclusion Criteria:
nonsteroidal antiinflammatory drugs, antalgics
Change in Lequesne index
assessment of algo-functional severity of pathology
Time frame: up to 2 years
Change in Womac index
assessment of symptom severity
Time frame: up to 2 years
Medical costs related to knee osteoarthritis
Time frame: up to 2 years
No study locations are listed for this record.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim